TY  - GEN
AU  - Abou-Alfa,G K
AU  - Qin,S
AU  - Ryoo,B-Y
AU  - Lu,S-N
AU  - Yen,C-J
AU  - Feng,Y-H
AU  - Lim,H Y
AU  - Izzo,F
AU  - Colombo,M
AU  - Sarker,D
AU  - Bolondi,L
AU  - Vaccaro,G
AU  - Harris,W P
AU  - Chen,Z
AU  - Hubner,R A
AU  - Meyer,T
AU  - Sun,W
AU  - Harding,J J
AU  - Hollywood,E M
AU  - Ma,J
AU  - Wan,P J
AU  - Ly,M
AU  - Bomalaski,J
AU  - Johnston,A
AU  - Lin,C-C
AU  - Chao,Y
AU  - Chen,L-T
TI  - Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
SN  - 1569-8041
PY  - 2019///1112
KW  - Carcinoma, Hepatocellular
KW  - pathology
KW  - Combined Modality Therapy
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Hydrolases
KW  - therapeutic use
KW  - Liver Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Palliative Care
KW  - Polyethylene Glycols
KW  - Prognosis
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdy101
ER  -